The University of Alabama at Birmingham will receive $670,729 from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research on DNA damage as a predictive biomarker for immunotherapy response in ovarian cancer. The three-year project grant awarded in July 2021 will support research to investigate medical solutions for the battlefield by exploring DNA damage as a potential predictor of whether patients with ovarian cancer will respond to immunotherapy treatments. The place of performance for the research is Birmingham, Alabama. The funding will allow the University of Alabama at Birmingham researchers to develop biomarkers to help guide future personalized treatment approaches for ovarian cancer patients.
Generated 1/6/24, 5:55 PM